Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study

Multinational Center for Quality of Life Research, Russia

Status: Unknown

Conditions: Relapsed and/or Refractory Multiple Myeloma

Treatments: Drug: ixazomib in combination with lenalidomide and dexamethasone

Study type: Observational

Funder types: Other

Identifiers

NCT03903406

IISR-2018-102607

Details and patient eligibility

About

The purpose of this pilot study is to examine changes in patient-reported outcomes in patients with RRMM receiving triple therapy with ixazomib in combination with LenDex in a real world setting as well as to analyze clinical outcomes and safety of this treatment modality.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients with confirmed diagnosis of RRMM
• At least 18 years of age at the time of treatment start
• Patients who have received at least one prior therapy and who are suitable for treatment with ixazomib in combination with LenDex
• Patients who gave informed consent
• Patients who are capable to fill out questionnaires
• Patients with expected life duration of at least 6 months

Exclusion criteria

• Patients currently enrolled in any other clinical trials
• Patients with contraindications to ixazomib in accordance with instruction for use.